Back

GRAPHICS

UTILITY OF AN ORAL PRESENTATION OF hCG (human Choriogonadotropin) FOR THE MANAGEMENT OF OBESITY. A DOUBLE-BLIND STUDY (IV)

Figure 4 (A,B,C and D): Plicometries on four "high-responsive" skinfolds.

Here it is shown a different series of skinfolds displaying a clear treatment-dependent behavior, most noticeable from the second week of treatment on. When last four treatment' weeks were submitted to study, MANOVA analysis resulted in nearly significant differences for factor TREATMENT and the INTERACTION.For each of these skinfolds, highly significant statistical results were found between G2 and P groups for the effect of the INTERACTION.
In this Figures we observe the percentages of skinfold thickness reductions, comparing data obtained at the end of the trial with the corresponding basal values (week zero).

P values resulting from Scheffé test are marked by asterisks as follows: * p<0.05, ** p<0.0005, *** p<10-4, # p<0.01, ## p<10-6. See other details in the legend of Fig. 3 and the text.

wpe15.gif (7653 bytes)

(Click to enlarge)

wpe5.gif (8110 bytes)

(Click to enlarge)

wpe3.gif (8937 bytes)

(Click to enlarge)

wpe1.gif (8029 bytes)

(Click to enlarge)

The hCG and obesity  Research Clinic
Director: Dr. Daniel Belluscio
Phone and Fax+54-11-4804 97 84
Phone+54-11-4807 18 83

Proceedings of the First International Workshop on hCG and obesity
(click here)


 




Copyright © Dr. Daniel Belluscio 1992-2007. All rights reserved



Supervised the translation and spelling of this website

05/06/2007